HCC
Conditions
Interventions
Case series:Apatinib
Sponsors
General Hospital of the People's Liberation Army of China
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old both male and female; 2. Patients with hepatocellular carcinoma after surgical resection or local ablation (PEI or percutaneous puncture or intraoperative RFA); 3. Postoperative pathology suggested that there was no residual on the cutting edge, and CR was confirmed by imaging within 3 to 7 weeks after surgery; 4. Preoperative imaging (CT/MRI/ pet-ct, etc.), intraoperative or postoperative pathology and other examinations suggested at least one high-risk factor for recurrence: Group 1: the number of tumors >=3; Group 2: differentiation degree for III or IV level (the Edmondson - Steiner level 4 (I - IV) classification method). Group 3: hepatic vein, portal vein, bile duct or inferior vena cava can be seen under the gross or microscopic view and can be surgically removed, except for single tumor with diameter =200ng/ml), and remained >=200 ng/ml 1 to 2 months after surgery. Group 5: tumor rupture; Group 6: there was no clear fibrous capsule or incomplete capsule between the tumor and liver tissue; Group 7: satellite nodules were found on the excised specimen; Group 8: tumor in special location (e.g. adjacent to left, middle, right or inferior vena cava); 5. Voluntarily join the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Proven allergic to apatinib mesylate tablets and/or their excipients; 2. Pregnant or nursing women; 3. Patients with apatinib contraindications; 4. The doctor thinks not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| effectiveness; | — |
Countries
China
Contacts
Public ContactKaishan Tao
The First Hospital Affiliated to The Fourth Military Medical University
Outcome results
None listed